New Document
Corporate Profile Products Investor Relations News Room Careers Contact Us Manufacturing Quality Assurance Environment, Health & Safety R & D Contract Research & Manufacturing Home
 


Financial Year 2007 - 2008

Quarter IV
(March 2008)

Quarter III
(December 2007)

Quarter II
(September 2007)

Quarter I
(June 2007)

Financial Year 2006 - 2007

Quarter IV
(March 2007)

Quarter III
(December 2006)

Quarter II
(September 2006)

Quarter I
(June 2006)
Financial Year 2005 - 2006

Quarter III
(December 2005)

Quarter II
(September 2005)

Quarter I
(June 2005)

Financial Year 2004 - 2005

Quarter IV
(March 2005)

Quarter III
(December 2004)

Quarter II
(September 2004)

Quarter I
(June 2004)

Financial Year 2003 - 2004

Quarter IV
(March 2004)

Quarter III
(December 2003)

Quarter II
(September 2003)

Quarter I
(June 2003)

Financial Year 2002 - 2003

Quarter IV
(March 2003)

Quarter III
(December 2002)

Quarter II
(September 2002)

Quarter I
(June 2002)

MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD - 500 003
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED
30TH JUNE 2007

(Rs.in Millions )
Sl.No Particulars Quarter ended 30th June Year ended
31st March 2007
(Audited)
2007 (Unaudited) 2006 (Unaudited)
01.


02.

03.
04.




05.


06.

07.
08.
09.
10.
11.
12.

13.

14.


 Sales (net)
- Exports
- Domestic
Income from Potential patent infringment suit
Other Income
Total Expenditure
a) (Increase) / Decrease in Stock
b) Consumption of Raw materials
c) Staff Cost
d) Other Expenditure
Profit Before R&D, Interest & Depreciation
(1+2+3-4)
Research and Development Expenditure
Interest
Depreciation
Profit Before Tax (5-6-7-8)
Provision for Tax (NET)
Profit After Tax (9-10)
Paid-up Equity Capital(Face value-Rs2/-each)
Reserves excluding revaluation reserves
E.P.S (Face value-Rs.2/-)
(Not Annualised)
      - Basic
      -  Diluted		 2061.01
1344.91
716.10
66.91

94.43
1577.84
41.26
1010.95
185.21
340.42


644.51

209.89
47.67
74.53
312.42
54.50
257.92
308.80

-



1.67
1.66		 1930.69
1148.26
782.43
66.91

76.28
1531.96
439.44
676.91
155.69
259.92


541.92

140.42
31.72
58.06
311.72
22.00
289.72
307.33

--



1.89
1.84
 7492.21
5051.77
2440.44
268.39

250.41
5730.22
(28.22)
3888.54
598.38
1271.52


2280.79

800.92
154.01
250.71
1075.15
79.02
996.13
308.24

9388.77



6.48
6.43
Notes :

  1. The above results were subjected to a limited review by the Auditors, reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 25th July 2007.
  2. The figures for the previous year / period have been rearranged wherever necessary to conform to current period's presentation.
  3. The activities of the Company relate to only one business segment i.e. Pharmaceuticals.
  4. During the Quarter 280,770 Equity Shares of Rs. 2/- each at a premium of Rs.141.13 were allotted, on exercise of stock options under the Employees Stock Option Scheme.
  5. Summary of Investor Complaints :
    Opening : Nil , Received during the quarter : 1 , Resolved : Nil , Closing : 1
  6. Provision for tax includes Current tax Rs 36.30 Millions (Quarter ended 30th June 2006 Rs 17 Millions), Deferred tax Rs 47.50 Millions (Quarter ended 30th June 2006 Rs 20 Millions) and Fringe benefit tax Rs 7 Million (Quarter ended 30th June 2006 Rs 2 Millions) and is net of MAT credit available of Rs 36.30 Millions (Quarter ended 30th June 2006 Rs 17 Millions).

  For and on behalf of the Board

Place : Pittsburgh, USA
Date : 25th July 2007
Rajiv Malik
Managing Director & Chief Executive Officer



MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD - 500 003
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED
30TH JUNE 2007

(Rs.in Millions )
Sl.No Particulars Quarter ended 30th June Year ended
31st March 2007
(Audited)
2007 (Unaudited) 2006 (Unaudited)
01.
02.

03.
04.




05.


06.

07.
08.
09.
10.
11.


12.
13.
14.
15.

16.

17.		 Sales (net)
Income from Potential patent infringment suit
Other Income
Total Expenditure
a) (Increase) / Decrease in Stock
b) Consumption of Raw materials
c) Staff Cost
d) Other Expenditure
Profit Before R&D, Interest & Depreciation
(1+2+3-4)
Research and Development Expenditure
Interest
Depreciation
Profit Before Tax (5-6-7-8)
Provision for Tax (NET)
Profit After Tax before Minority Interest and Share in Associates(9-10)
Less:Minority Interest
Less:Share of loss in Associate
Net Profit(11-12-13)
Paid-up Equity Capital(Face value Rs2/-each)
Reserves excluding revaluation reserves
E.P.S(Face value Rs2/-)(Not annualised)
      - Basic
      - Diluted		 4470.16
66.91

105.24
3636.59
425.01
2039.54
456.27
715.77


1005.72

292.04
208.01
149.34
356.33
107.51


248.82
20.02
0.00
268.84
308.80

-



1.74
1.73		 4421.60
66.91

72.62
3709.06
456.46
2122
156.91
137.30


852.07

177.02
156.91
137.30
380.84
25.16


355.68
(15.16)
(2.50)
338.02
307.33

-



2.20
2.15		 16480.27
268.39

275.95
13750.74
(250.84)
9231.11
1773.35
2997.12


3273.87

1007.56
704.19
540.70
1021.42
264.89


756.53
6.57
0.00
763.10
308.24

10193.55



4.96
4.93
Segment Information :

Segment Revenue :
- Pharmaceuticals
- Medical Supplies
Less: Inter segment Revenue
Net Segment Revenue

Segment Results :
Profit before tax and interest from each segment
- Pharmaceuticals
- Medical Supplies
Total
Less: Interest
Other unallocable Income /(Expenditure)
Total Profit before tax

Capital Employed :
- Pharmaceuticals
- Medical Supplies
- Unallocable
Total Capital Employed



4076.82
393.34

4470.16




542.17
22.17
564.34
(208.81)


356.33


14948.27
413.01
11384.18
26745.45


3806.37
615.23

4421.60




504.97
32.78
537.75
(156.91)


380.84


12318.00
261.74
11517.41
24097.15


14283.02
2197.25

16480.27




1627.41
98.20
1725.61
(704.19)


1021.42


15403.30
188.21
11920.21
27511.72
Notes :

  1. The above results were reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 25th July 2007.
  2. The results include the operations of Subsidiaries - Matrix Laboratories BV, Matrix Laboratories Nv, Docpharma Nv & its subsidiaries, Matrix Singapore Pvt Ltd. Mchem Group, China, Matrix Inc, USA and Concord Biotech Limited, India and Joint Ventures Astrix Laboratories Limited, India and Fine Chemicals Corporation, South Africa.
  3. The Company became a subsidiary of MP Laboratories (Mauritius) Limited, with effect from 8th January 2007. The ultimate holding company is Mylan Laboratories Inc, USA.
  4. The figures for the previous year / period have been rearranged where ever neccessary to conform to current period's presentation.

  For and on behalf of the Board

Place : Pittsburgh, USA
Date : 25th July 2007
Rajiv Malik
Managing Director & Chief Executive Officer


Foote Page

Corporate Profile | Products | Investor Relations | News Room | Careers | Contact Us
Manufacturing | Quality Assurance | Environment, Health & Safety | R & D

© 2003 Matrix Laboratories Limited. All rights reserved.
This site is best viewed in IE 4 or later or Netscape 4.7 or later
Designed and Developed by emazines software pvt. ltd.